



1. (Previously Presented) A compound represented by the formula:



wherein ring A represents benzene ring optionally having a further substituent,

-L- represents -O-, -NR<sup>3a</sup>-, -S-, -SO-, -SO<sub>2</sub>-, -SO<sub>2</sub>NR<sup>3a</sup>-, -SO<sub>2</sub>NHCONR<sup>3a</sup>-,

-SO<sub>2</sub>NHC(=NH)NR<sup>3a</sup>-, -C(=S)-,



or -CONR<sup>3a</sup>-


wherein R<sup>3a</sup> and R<sup>3b</sup> represent independently hydrogen atom, cyano group,

hydroxy group, amino group, a C<sub>1-6</sub> alkyl group or a C<sub>1-6</sub> alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R<sup>1</sup> represents a hydrocarbon group optionally having a substituent or a group represented by the formula:



wherein R<sup>7</sup> represents a hydrocarbon group optionally having a substituent,

R<sup>2</sup> represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,


X represents a bond,

k and m are each independently an integer of 0 to 4 and  $k + m = 4$ ,

or a salt thereof.

2. (Original) The compound according to claim 1, wherein n is an integer of 1 to 6.

3. (Original) The compound according to claim 1, wherein -L- is -O-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -CHOH-,



4. (Original) The compound according to claim 1, wherein X is a bond and  $k=m=2$ .

5. (Original) The compound according to claim 1, wherein X is a bond,  $k=3$  and  $m=1$ .

6. (Cancelled)

7. (Original) The compound according to claim 1, wherein R is hydrogen atom.

8. (Currently Amended) The compound according to claim 1, wherein n is an integer of 2 to 4.


9. (Original) The compound according to claim 1, wherein R<sup>1</sup> is a C<sub>7-16</sub> aralkyl group optionally having a substituent.

10. (Original) The compound according to claim 1, wherein R<sup>2</sup> is a C<sub>7-16</sub> aralkyl group optionally having a substituent.
11. (Original) The compound according to claim 1, wherein R is hydrogen atom, n is an integer of 2 to 4, and R<sup>1</sup> and R<sup>2</sup> are benzyl group optionally having a substituent.
12. (Previously Presented) A compound selected from the group consisting of
- 2-[(2-methylphenyl)methyl]-7-[2-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
- 2-[(2-methylphenyl)methyl]-8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
- 3-[1-(phenylmethyl)-4-piperidinyl]-1-[3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]-1-propanone oxime,
- 2-[1-[3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]-3-[1-(phenylmethyl)-4-piperidinyl]propylidene]malononitrile,
- 3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-1H-3-benzazepine,
- 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,
- 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,
- 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,

8-[3-[1-[[3-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]propoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 4-[[4-[2-[[2-[(2-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-1-benzenecarboxyimidamide,  
 8-[2-[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2-[(2-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 2-(phenylmethyl)-8-[2-[1-[[4-(N,N-diethylaminomethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 2-[(2-methylphenyl)methyl]-8-[2-[1-[[3-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 2-[(2-methylphenyl)methyl]-8-[2-[1-[4-(4,5-dihydro-1H-2-imidazolyl)benzoyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 2-(phenylmethyl)-7-[[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 2-(phenylmethyl)-8-[[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 2-(phenylmethyl)-8-[2-[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 and 2-(phenylmethyl)-8-[2-[1-[(4-dimethylaminophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,  
 or a salt thereof.

13. (Cancelled)

14. (Previously Presented) A process for producing the compound according to claim 1, which comprises reacting a compound represented by the formula:




wherein respective symbols represent the same meanings as those for claim 1 or a salt thereof

with a compound represented by the formula:  $R^1-Z^1$

wherein  $Z^1$  represents a leaving group and  $R^1$  represents the same meaning as that for claim 1 or a salt thereof.


15. (Previously Presented) A compound represented by the formula:



wherein ring A represents benzene ring optionally having a further substituent,

-La- represents  $-NR^{3a}$ -,  $-S$ -,  $-SO$ -,  $-SO_2$ -,  $-SO_2NR^{3a}$ -,  $-SO_2NHCONR^{3a}$ -,

$-SO_2NHC(=NH)NR^{3a}$ -,  $-C(=S)$ -,




or  $-CONR^{3a}$ -

wherein  $R^{3a}$  and  $R^{3b}$  represent independently hydrogen atom, cyano group, hydroxy group, amino group, a  $C_{1-6}$  alkyl group or a  $C_{1-6}$  alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R<sup>1a</sup> represents hydrogen atom or a group represented by the formula:



wherein R<sup>8</sup> represents a hydrocarbon group optionally having a substituent,

R<sup>2</sup> represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,


X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof.

16. (Cancelled)


17. (Previously Presented) A pharmaceutical composition comprising a compound represented by the formula:



wherein ring A represents benzene ring optionally having a further substituent,

-L- represents -O-, -NR<sup>3a</sup>-, -S-, -SO-, -SO<sub>2</sub>-, -SO<sub>2</sub>NR<sup>3a</sup>-, -SO<sub>2</sub>NHCONR<sup>3a</sup>-,

-SO<sub>2</sub>NHC(=NH)NR<sup>3a</sup>-, -C(=S)-,




or -CONR<sup>3a</sup>-

wherein R<sup>3a</sup> and R<sup>3b</sup> represent independently hydrogen atom,  
cyano group, hydroxy group, amino group, a C<sub>1-6</sub> alkyl  
group or a C<sub>1-6</sub> alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and  
may be different in repetition of n,

R<sup>1</sup> represents a hydrocarbon group optionally having a substituent or a group  
represented by the formula:



wherein R<sup>7</sup> represents a hydrocarbon group optionally having a  
substituent,

R<sup>2</sup> represents hydrogen atom, an acyl group, a hydrocarbon group optionally  
having a substituent or a heterocyclic group optionally having a  
substituent,

X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof

and a pharmacologically acceptable carrier.

Claims 18-21 (Cancelled).

22. (Original) A method for treating obesity and obesity-based diseases, which comprises administering an effective amount of the compound according to claim 1 to a mammal.

Claims 23-42 (Cancelled)

43. (Previously Presented) A method for promoting thermal production in a mammal in need thereof, which comprises administering an effective amount of a compound or a salt thereof according to claim 1 to said mammal.

44. (Previously Presented) A method for promoting lipolysis in a mammal in need thereof, which comprises administering an effective amount of a compound or salt thereof according to claim 1 to said mammal.